MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 621.88 Million EUR | 88.53% |
| 2022 | 329.86 Million EUR | 2.4% |
| 2021 | 322.13 Million EUR | 2.35% |
| 2020 | 314.72 Million EUR | 685.99% |
| 2019 | 40.04 Million EUR | 55888.9% |
| 2018 | 71.51 Thousand EUR | -18.53% |
| 2017 | 87.78 Thousand EUR | -59.79% |
| 2016 | 218.29 Thousand EUR | -2.98% |
| 2015 | 225 Thousand EUR | -10.6% |
| 2014 | 251.67 Thousand EUR | -15.72% |
| 2013 | 298.6 Thousand EUR | 305.68% |
| 2012 | 73.6 Thousand EUR | 0.0% |
| 2011 | 73.6 Thousand EUR | -42.31% |
| 2010 | 127.59 Thousand EUR | 290.55% |
| 2009 | 32.67 Thousand EUR | -32.87% |
| 2008 | 48.67 Thousand EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| 2003 | - EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 246.67 Million EUR | -60.33% |
| 2023 FY | 621.88 Million EUR | 88.53% |
| 2023 Q3 | 242.16 Million EUR | -12.24% |
| 2023 Q1 | 275.05 Million EUR | -16.62% |
| 2023 Q4 | 621.88 Million EUR | 156.8% |
| 2023 Q2 | 275.94 Million EUR | 0.32% |
| 2022 Q2 | 326.4 Million EUR | 1.11% |
| 2022 Q1 | 322.83 Million EUR | 0.22% |
| 2022 Q3 | 289.47 Million EUR | -11.32% |
| 2022 Q4 | 329.86 Million EUR | 13.96% |
| 2022 FY | 329.86 Million EUR | 2.4% |
| 2021 Q4 | 322.13 Million EUR | 0.61% |
| 2021 FY | 322.13 Million EUR | 2.35% |
| 2021 Q1 | 316.62 Million EUR | 0.61% |
| 2021 Q2 | 318.27 Million EUR | 0.52% |
| 2021 Q3 | 320.18 Million EUR | 0.6% |
| 2020 Q1 | 44.82 Million EUR | 11.95% |
| 2020 FY | 314.72 Million EUR | 685.99% |
| 2020 Q4 | 314.72 Million EUR | 631.85% |
| 2020 Q3 | 43 Million EUR | -2.25% |
| 2020 Q2 | 43.99 Million EUR | -1.87% |
| 2019 Q3 | 40.69 Million EUR | 7.75% |
| 2019 FY | 40.04 Million EUR | 55888.9% |
| 2019 Q1 | 38.33 Million EUR | 53504.11% |
| 2019 Q2 | 37.76 Million EUR | -1.49% |
| 2019 Q4 | 40.04 Million EUR | -1.6% |
| 2018 Q3 | 71.51 Thousand EUR | -18.06% |
| 2018 Q2 | 87.28 Thousand EUR | -0.57% |
| 2018 Q1 | 87.78 Thousand EUR | 0.0% |
| 2018 Q4 | 71.51 Thousand EUR | 0.0% |
| 2018 FY | 71.51 Thousand EUR | -18.53% |
| 2017 FY | 87.78 Thousand EUR | -59.79% |
| 2017 Q4 | 87.78 Thousand EUR | -29.94% |
| 2017 Q3 | 125.3 Thousand EUR | -7.27% |
| 2017 Q2 | 135.12 Thousand EUR | -38.1% |
| 2017 Q1 | 218.29 Thousand EUR | 0.0% |
| 2016 Q1 | 225 Thousand EUR | 0.0% |
| 2016 Q2 | 225 Thousand EUR | 0.0% |
| 2016 Q4 | 218.29 Thousand EUR | -2.98% |
| 2016 Q3 | 225 Thousand EUR | 0.0% |
| 2016 FY | 218.29 Thousand EUR | -2.98% |
| 2015 Q1 | 249.69 Thousand EUR | -0.79% |
| 2015 Q2 | 247.38 Thousand EUR | -0.93% |
| 2015 Q3 | 244.25 Thousand EUR | -1.27% |
| 2015 Q4 | 225 Thousand EUR | -7.88% |
| 2015 FY | 225 Thousand EUR | -10.6% |
| 2014 Q3 | 273.04 Thousand EUR | -2.3% |
| 2014 FY | 251.67 Thousand EUR | -15.72% |
| 2014 Q2 | 279.48 Thousand EUR | -6.4% |
| 2014 Q4 | 251.67 Thousand EUR | -7.83% |
| 2014 Q1 | 298.6 Thousand EUR | 0.0% |
| 2013 Q3 | 298.6 Thousand EUR | 305.68% |
| 2013 Q4 | 298.6 Thousand EUR | 0.0% |
| 2013 FY | 298.6 Thousand EUR | 305.68% |
| 2013 Q1 | 73.6 Thousand EUR | 0.0% |
| 2013 Q2 | 73.6 Thousand EUR | 0.0% |
| 2012 Q3 | 73.6 Thousand EUR | 0.0% |
| 2012 Q4 | 73.6 Thousand EUR | 0.0% |
| 2012 FY | 73.6 Thousand EUR | 0.0% |
| 2012 Q1 | 73.6 Thousand EUR | 0.0% |
| 2012 Q2 | 73.6 Thousand EUR | 0.0% |
| 2011 FY | 73.6 Thousand EUR | -42.31% |
| 2011 Q3 | 159.71 Thousand EUR | 9.74% |
| 2011 Q4 | 73.6 Thousand EUR | -53.91% |
| 2011 Q2 | 145.54 Thousand EUR | 3.75% |
| 2011 Q1 | 140.27 Thousand EUR | 9.94% |
| 2010 Q1 | 32.67 Thousand EUR | 0.0% |
| 2010 FY | 127.59 Thousand EUR | 290.55% |
| 2010 Q3 | 114.44 Thousand EUR | 250.3% |
| 2010 Q4 | 127.59 Thousand EUR | 11.49% |
| 2010 Q2 | 32.67 Thousand EUR | 0.0% |
| 2009 FY | 32.67 Thousand EUR | -32.87% |
| 2009 Q4 | 32.67 Thousand EUR | 0.0% |
| 2008 FY | 48.67 Thousand EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| 2003 FY | - EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -2874.231% |
| Evofem Biosciences, Inc. | 8000.00 USD | -7773423.375% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -35325.196% |
| Mesoblast Limited | 100.29 Million USD | -520.053% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -1060371.795% |
| Genus plc | 228.2 Million USD | -172.516% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -93117.634% |
| ContraFect Corporation | 2.21 Million USD | -28039.451% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -44227.236% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -11360.134% |
| MultiCell Technologies, Inc. | 36.43 USD | -1707059658.441% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -1018.251% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -27837.191% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -50526.963% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -274.391% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -32657.037% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -363085.114% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -11282227.104% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -2169.76% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -193031.016% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 94.467% |
| Halberd Corporation | 150 Thousand USD | -414487.913% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -207193.957% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -378622.859% |
| argenx SE | 15.35 Million USD | -3950.292% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -2961.648% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -13955956.329% |
| Genscript Biotech Corporation | 287.12 Million USD | -116.586% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -492276.898% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -271119.485% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -112033.625% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -2458028.266% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -7425.192% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -234011.42% |
| ONE Bio Corp. | 592.19 Thousand USD | -104912.491% |
| Reve Technologies, Inc. | 1064.00 USD | -58447444.173% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -415557.539% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -415557.539% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -270647.165% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -440950.972% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -777252.338% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -7852.494% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -168409.296% |
| International Stem Cell Corporation | 445 Thousand USD | -139648.735% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -7530.452% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -135979.184% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -53464.33% |
| PureTech Health plc | 18.25 Million USD | -3307.572% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -414487.913% |
| IXICO plc | 275 Thousand USD | -226038.862% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -5152.824% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -2263.761% |
| CSL Limited | 11.23 Billion USD | 94.467% |
| Cellectis S.A. | 36.21 Million USD | -1617.377% |